Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder

Open-label, single-group treatment study of up to 12 adult outpatients with body dysmorphic disorder receiving a single oral 25 mg dose of psilocybin with intensive therapeutic support.

Procedures follow prior psilocybin depression protocols: preparation and support from two therapists including 8–9 hours on dosing day, resting-state fMRI pre- and 1 day post-dose, and safety/clinical assessments at day 1, week 1, and months 1, 2, and 3.